Representative Jefferson Shreve (R-Indiana) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $50,001 and $100,000 in Johnson & Johnson stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
- Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
- Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
- Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
- Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
- Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
- Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
- Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
- Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.
- Sold $100,001 - $250,000 in shares of Walmart NYSE: WMT on 5/12/2025.
Johnson & Johnson Stock Performance
Johnson & Johnson stock traded down $1.27 during midday trading on Friday, hitting $168.29. The company's stock had a trading volume of 6,199,690 shares, compared to its average volume of 8,375,731. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The company has a 50-day moving average price of $156.08 and a two-hundred day moving average price of $155.78. The company has a market cap of $404.92 billion, a price-to-earnings ratio of 18.00, a PEG ratio of 2.16 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 EPS. The business's revenue was up 5.8% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.09%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.
Institutional Investors Weigh In On Johnson & Johnson
Institutional investors have recently added to or reduced their stakes in the business. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $29,000. Conquis Financial LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $33,000. GFG Capital LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $35,000. Finally, Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $36,000. 69.55% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
JNJ has been the subject of several analyst reports. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Raymond James Financial dropped their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. UBS Group boosted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Finally, Morgan Stanley boosted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $174.50.
View Our Latest Stock Report on Johnson & Johnson
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
